Recursion Pharmaceuticals, Inc. (RXRX)
3.43
+0.05
(+1.48%)
USD |
NASDAQ |
Sep 03, 16:00
3.41
-0.02
(-0.58%)
After-Hours: 19:56
Recursion Pharmaceuticals Cash from Investing (Quarterly) : -1.959M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.959M |
| March 31, 2026 | -0.338M |
| December 31, 2025 | -1.244M |
| September 30, 2025 | -2.549M |
| June 30, 2025 | -5.808M |
| March 31, 2025 | -7.27M |
| December 31, 2024 | 275.46M |
| September 30, 2024 | -4.562M |
| June 30, 2024 | -4.182M |
| March 31, 2024 | -6.653M |
| December 31, 2023 | -2.488M |
| September 30, 2023 | -0.347M |
| June 30, 2023 | -2.053M |
| Date | Value |
|---|---|
| March 31, 2023 | -5.34M |
| December 31, 2022 | -7.979M |
| September 30, 2022 | 52.98M |
| June 30, 2022 | 4.94M |
| March 31, 2022 | 143.30M |
| December 31, 2021 | -52.24M |
| September 30, 2021 | -193.87M |
| June 30, 2021 | -6.212M |
| March 31, 2021 | -19.42M |
| December 31, 2020 | -4.591M |
| September 30, 2020 | -3.426M |
| June 30, 2020 | -0.039M |
| March 31, 2020 | -0.684M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Twist Bioscience Corp. | -10.20M |
| Absci Corp. | 24.07M |
| Novavax, Inc. | 34.90M |
| Editas Medicine, Inc. | -29.80M |
| Halozyme Therapeutics, Inc. | -62.66M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -105.95M |
| Cash from Financing (Quarterly) | -1.267M |
| Free Cash Flow | -354.26M |
| Free Cash Flow Per Share (Quarterly) | -0.2027 |
| Free Cash Flow to Equity (Quarterly) | -102.17M |
| Free Cash Flow to Firm (Quarterly) | -107.60M |
| Free Cash Flow Yield | -20.30% |